P/E at 30.6 vs Industry's 36.8: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 30.60, which is approximately 16.7% below the Pharmaceuticals & Biotechnology industry average of 36.76. This discount suggests that the market is pricing in either a relative earnings risk or subdued growth expectations compared to peers. Given the sector’s elevated valuations, this gap may reflect concerns over recent performance or structural challenges within the company’s business model. Dr Reddys Laboratories Ltd’s valuation contrasts with the broader industry, raising the question what is the current rating? that factors in this premium-discount dynamic.

Performance Across Timeframes: Divergent Momentum

Examining returns over multiple periods reveals a nuanced performance profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 7.18%, underperforming the Sensex’s 5.44% fall. This underperformance extends to shorter intervals, with the stock down 1.42% over one week and 1.79% over one month, while the Sensex posted modest gains or smaller losses in these periods.

Most strikingly, the three-month return shows a steep 10.12% decline, contrasting sharply with the Sensex’s 3.13% gain. This divergence suggests a recent acceleration in negative momentum, possibly linked to company-specific developments or sector rotation. However, the year-to-date performance of -6.77% is less severe than the Sensex’s -9.01%, indicating some resilience earlier in the year. Is this a temporary setback or a sign of deeper issues? The data invites further scrutiny.

Moving Average Configuration: Mixed Technical Signals

The technical picture for Dr Reddys Laboratories Ltd is equally complex. The stock currently trades above its 20-day moving average but remains below the 5-day, 50-day, 100-day, and 200-day moving averages. This configuration indicates a short-term recovery attempt within a broader downtrend. The fact that the price is above the 20-day MA but below longer-term averages suggests a potential relief rally rather than a confirmed trend reversal — is this a genuine recovery or a dead-cat bounce? — the moving average configuration provides the clearest answer.

Relative Performance vs Sensex: A Mixed Record

Over longer horizons, Dr Reddys Laboratories Ltd has lagged the Sensex. The three-year return is a mere 0.29% compared to the Sensex’s robust 18.90%. Similarly, the five-year gain of 30.09% trails the Sensex’s 40.14%, and the ten-year return of 96.75% is significantly below the Sensex’s 176.17%. These figures highlight a persistent underperformance trend relative to the broader market, despite the company’s mid-cap stature and sector prominence.

Sector Context: Pharmaceuticals & Biotechnology Results

The Pharmaceuticals & Biotechnology sector has seen mixed results recently, with 34 stocks having declared results: 14 positive, 15 flat, and 5 negative. This distribution suggests a broadly stable sector environment with pockets of strength and weakness. Dr Reddys Laboratories Ltd’s underperformance relative to the sector’s mixed results raises questions about company-specific factors influencing its trajectory — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Rating Context: Previously Hold, Now Reassessed

The stock was previously rated Hold by MarketsMOJO before its rating was updated on 13 Jul 2026. While the current rating is not disclosed, the reassessment coincides with the stock’s valuation discount and recent performance trends. This update reflects a comprehensive four-parameter analysis that incorporates valuation, momentum, technicals, and sector context — what is the current rating?

Conclusion: A Complex Data Story

The data for Dr Reddys Laboratories Ltd paints a picture of a stock trading at a valuation discount to its sector, yet grappling with recent momentum challenges and a mixed technical setup. Its underperformance relative to the Sensex across multiple timeframes, combined with a moving average configuration signalling a tentative short-term bounce within a longer downtrend, suggests caution. The sector’s broadly stable results contrast with the stock’s sharper declines, emphasising company-specific factors at play. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today